Multiple clinical trials, including PALOMA, MONALEESA, and DAWNA, have investigated the safety and efficacy of ET with CDK4/6 inhibitors in the treatment of HR+/HER2− BC [301]. The gene discussed is CDK4; the disease is breast cancer.